Christopher Boerner is the new CEO of Bristol Myers Squibb, stepping into his role on November 1, 2023. Before this, he held various important positions within the company since joining in 2015, showing a steady rise through roles like Chief...

Christopher Boerner is the new CEO of Bristol Myers Squibb, stepping into his role on November 1, 2023. Before this, he held various important positions within the company since joining in 2015, showing a steady rise through roles like Chief Commercialization Officer and Head of International Markets. Boerner holds a Ph.D. in Economics from Duke University and has a solid background in healthcare strategy. His leadership style focuses on innovation and adaptability, which is crucial in the fast-paced biopharmaceutical industry. In 2023, Boerner's compensation was $1.86 million, with a base salary of $1.5 million and no bonuses as he aims for long-term goals aligned with shareholder interests. Interestingly, he has around $18.9 million worth of stock in Bristol Myers Squibb, which reflects his confidence in the company's future. This stock includes over 101,205 shares and marks a significant portion of his personal wealth. During his time as CEO, Boerner is expected to drive Bristol Myers Squibb towards a path of sustainable growth while continuing to advance their mission of developing innovative therapies that address serious health issues.